Oncology · ImmunotherapyTrial Updateclinicalmid-term

Phase 2 Trial of Botensilimab + Balstilimab in Chemo-refractory Colorectal Cancer

The ongoing Phase 2 trial of botensilimab and balstilimab represents a significant opportunity for Agenus Inc. to establish a foothold in the competitive landscape of colorectal cancer therapies. Monitoring the trial's outcomes is crucial for assessing the potential impact on treatment options and market positioning.

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/7/2026, 12:31:09 AM

Assessment confidence: 64% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing Phase 2 trial of botensilimab and balstilimab represents a significant opportunity for Agenus Inc. Monitoring the trial's outcomes is crucial for assessing the potential impact on treatment options and market positioning. Regulatory context from FDA (FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients) supports the near-term read. Assessment grounded in 8 ranked evidence items (3 high-relevance).

Strategic Assessment

Portfolio teams should monitor trial outcomes to assess the viability of botensilimab and balstilimab as competitive agents in the oncology space. The strongest clinical anchor is Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma (ClinicalTrials.gov), sub-indication match (colorectal cancer); entity match (botensilimab). In colorectal cancer, 0 regulatory and 2 competitive items passed relevance filtering for botensilimab.

Competitive Pressure

The most relevant competitive pressure comes from FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer (Humanexa Signals) — sub-indication match (colorectal cancer); sponsor/company relevance (roche). Secondary pressure from New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy.

Regulatory Outlook

Regulatory risk is concentrated around The trial's findings will be critical for future regulatory submissions, influencing approval pathways and labeling for these immunotherapy agents..

Key Risks

Elevated medium regulatory exposure for botensilimab could delay market entry or constrain labeling if agency review intensifies.
Evidence gap: no medium- or high-relevance regulatory precedents in ingested corpus.

Key Opportunities

Successful trial results could enhance Agenus Inc.'s market share in the oncology sector, particularly in the challenging area of unresectable colorectal cancer, potentially leading to increased revenue streams.
Portfolio teams should monitor trial outcomes to assess the viability of botensilimab and balstilimab as competitive agents in the oncology space.

What Would Change This Assessment

This becomes more urgent if Key milestones include interim results on survival rates and quality of life metrics, as well as safety data.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAlow relevance
Regulatory pathway relevance (approval); Broad oncology match without sub-indication specificity
FDA document
View source

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma
ClinicalTrials.govhigh relevance
Sub-indication match (colorectal cancer); Entity match (botensilimab)
FDA document
View source
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
ClinicalTrials.govlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer
Humanexa Signalshigh relevance
Sub-indication match (colorectal cancer); Sponsor/company relevance (Roche)
New Orthotopic Model Reveals CD8⁺ T Cell Dysfunction in Colorectal Cancer Immunotherapy
Humanexa Signalsmedium relevance
Sub-indication match (colorectal cancer)

Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
PubMedhigh relevance
Sub-indication match (colorectal cancer)
FDA document
View source
An orthotopic organoid-based model to study early CD8⁺ T cell dysfunction and immunotherapy response in colorectal cancer.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedmedium relevance
Sub-indication match (colorectal cancer)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedlow relevance
Broad oncology match without sub-indication specificity
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

botensilimab
balstilimab

Commercial impact

medium

Successful trial results could enhance Agenus Inc.'s market share in the oncology sector, particularly in the challenging area of unresectable colorectal cancer, potentially leading to increased revenue streams.

Regulatory impact

medium

The trial's findings will be critical for future regulatory submissions, influencing approval pathways and labeling for these immunotherapy agents.

What to watch

Key milestones include interim results on survival rates and quality of life metrics, as well as safety data.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.